Abstract
Background: Amiodarone hydrochloride has been in use for two decades for the control of ventricular and supraventricular arrhythmias. Established and emerging evidence indicates that amiodarone has an antiarrhythmic efficacy superior to that of most other drugs.
Hypothesis: The study was undertaken to evaluate the efficacy and acceptability of low‐dose amiodarone therapy in the long‐term management of supraventricular and ventricular tachyarrhythmias.
Methods: A total of 124 patients with symptomatic drug‐refractory or life‐threatening arrhythmias managed with low‐dose oral amiodarone therapy over a 10‐year period was analyzed retrospectively. Of these, 45 patients (36%) had ventricular arrhythmias, 52 (42%) had atrial arrhythmias, and 27 (22%) had atrioventricular reentry tachycardia. Loading doses of amiodarone 600 mg daily for 1 week were administered for supraventricular arrhythmias and 600–1200 mg daily for 2 weeks for ventricular arrhythmias. Maintenance daily doses were 194 ± 48 and 206 ± 55 mg, respectively. Mean treatment duration was 32 ± 28 months, with 326.3 patient years of therapy.
Results: Of 39 patients with sustained ventricular tachyarrhythmias, the actuarial incidence of satisfactory arrhythmia control (absence of sudden cardiac death or nonfatal arrhythmia recurrence) was 78% at 1 year and 71 % at 2 years. Satisfactory control of supraventricular arrhythmias (mean ventricular rate < 100/min with significant symptomatic improvement for sustained atrial arrhythmias and < 1 attack per year for paroxysmal atrial or atrioventricular arrhythmias) was achieved in 73, 65, and 62% of patients at 1, 2, and 3 years, respectively. The cumulative incidence of amiodarone‐related adverse effects was 5.8 per 100 patient years, with drug withdrawal required in 12 patients (9.7%). Fifteen patients had thyroid dysfunction, 2 had hepatic toxicity, and 1 developed nonfatal pulmonary fibrosis. Overall, the incidence of successful use of amiodarone (satisfactory arrhythmia control and freedom from side effects) was 67, 59, and 53% at 1, 2, and 3 years, respectively.
Conclusions: The results of this study suggest that the efficacy of low‐dose amiodarone therapy in the management of serious ventricular and supraventricular arrhythmias would be similar to those achieved with higher doses, but with a much more acceptable side effect profile.
Keywords: amiodarone hydrochloride, supraventricular arrhythmias, ventricular arrhythmias, low maintenance dose
Full Text
The Full Text of this article is available as a PDF (675.7 KB).
References
- 1. Rosenbaum MB, Chiale PA, Ryba D, Elizari MV: Control of tachyarrhythmias associated with Wolff‐Parkinson‐White syndrome by amiodarone hydrochloride. Am J Cardiol 1974; 4: 215–223. [DOI] [PubMed] [Google Scholar]
- 2. Mason JW: Drug therapy: Amiodarone. N Engl J Med 1988; 316: 455–466. [DOI] [PubMed] [Google Scholar]
- 3. Greene HL, Graham EL, Werner JA, Sears GK, Gorham JR, Kudenchuk PJ, Trobaugh GB: Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias. J Am Coll Cardiol 1983; 2: 1114–1128. [DOI] [PubMed] [Google Scholar]
- 4. Fogoros RN, Anderson KP, Winkle RA, Swerdiow CD, Mason JW: Amiodarone: Clinical efficacy and toxicity in 96 patients with recurrent, drug‐refractory arrhythmias. Circulation 1983; 68: 88–94. [DOI] [PubMed] [Google Scholar]
- 5. Smith WM, Lubbe WF, Whitlock RM, Mercer J, Rutherford JR, Roche AH: Long term tolerance of amiodarone treatment for cardiac arrhythmias. Am J Cardiol 1986; 57: 1288–1293. [DOI] [PubMed] [Google Scholar]
- 6. Herre JM, Sauve MJ, Malone P, Griffin JC, Helmy I, Langberg JJ, Goldberg H, Scheinman MM: Long‐term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol 1989; 13: 442–449. [DOI] [PubMed] [Google Scholar]
- 7. Harris L, McKenna WJ, Rowland E, Krikler DM: Amiodarone: Side effects of long‐term therapy. Circulation 1983; 67: 45–51. [DOI] [PubMed] [Google Scholar]
- 8. McGovem B, Garan H, Kelly E, Ruskin JN: Adverse reactions during treatment with amiodarone hydrochloride. Br Med J 1983; 287: 175–180. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Wilson JS, Podrid PJ: Side effects from amiodarone. Am Heart J 1991; 121: 158–171. [DOI] [PubMed] [Google Scholar]
- 10. Singh BN: Arrhythmia control by prolonging repolarization: The concept and its potential therapeutic impact. Eur Heart J 1993; 14 (suppl 15): 14–23. [DOI] [PubMed] [Google Scholar]
- 11. Kowey PR, Friehling TD, Marinchak RA, Sulpizi AM: Stohler JL: Safety and efficacy of amiodarone: The low‐dose perspective. Chest 1988; 93: 54–59. [DOI] [PubMed] [Google Scholar]
- 12. Weinberg BA, Miles WM, Klein LS, Bolander JE, Dusman RE, Stanton MS, Heger JJ, Langefeld C, Zipes DP: Five‐year follow‐up of 589 patients treated with amiodarone. Am Heart J 1993; 125: 109–120. [DOI] [PubMed] [Google Scholar]
- 13. Middlekauff HR, Wiener I, Stevenson WG: Low‐dose amiodarone for atrial fibrillation. Am J Cardiol 1993; 72: 75F–81F. [DOI] [PubMed] [Google Scholar]
- 14. Gosselink ATM, Crijns HJGM, Van Gelder IC, Hillige H, Wiesfeld CP, Lie KI: Low‐dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. J Am Med Assoc 1992; 267: 3289–3293. [PubMed] [Google Scholar]
- 15. Scheinman MM: NASPE policy statement: NASPE survey on catheter ablation. PACE 1995; 18: 1474–1478. [DOI] [PubMed] [Google Scholar]
- 16. CASCADE Investigators : Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). Am J Cardiol 1993; 72: 280–287. [DOI] [PubMed] [Google Scholar]
- 17. Siebels J, Cappato R, Ruppel R, Schneider MAE, Kuck KH, and the CASH Investigators : Preliminary results of the Cardiac Arrest Study Hamburg (CASH). Am J Cardiol 1993; 72: 109F–113F. [DOI] [PubMed] [Google Scholar]
- 18. Singh BN: Choice and chance in drug therapy of cardiac arrhythmias: Technique versus drug‐specific responses in evaluation of efficacy. Am J Cardiol 1993; 72: 114F–124F. [DOI] [PubMed] [Google Scholar]
- 19. Pfisterer ME, Kiowski W, Brunner H, Burckhardt D, Burkart F: Long‐term benefit of 1‐year amiodarone treatment for persistent complex ventricular arrhythmias after myocardial infarction. Circulation 1993; 87: 309–311. [DOI] [PubMed] [Google Scholar]
- 20. Ceremuzynski L, Kleczar E, Krzeminska‐Pakula M, Kuch J, Nartowicz E, Smielak‐Korombel J, Dyduszynski A, Maciejewicz J, Zaleska T, Lazarczyk‐Keedzia E, Motyka J, Paczkowska B, Sczaniecka O, Yusuf S: Effect of amiodarone on mortality after myocardial infarction: A double‐blind, placebo‐controlled, pilot study. J Am Coll Cardiol 1992; 20: 1056–1062. [DOI] [PubMed] [Google Scholar]
- 21. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R: Randomized trial of low‐dose amiodarone in severe congestive heart failure. Lancet 1994; 34: 493–498. [DOI] [PubMed] [Google Scholar]